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Feline leukemia virus (FeLV) subgroup T uses both a multiple membrane-spanning receptor, FePit1, and a soluble cofactor, FeLIX, to enter
feline cells. FeLIX is expressed from endogenous FeLV-related sequence and resembles the receptor binding domain (RBD) of the viral envelope
protein. It remains unclear whether FeLV-T receptor activity requires specific residues within FePit1 and FeLIX and/or a threshold level of
receptor/cofactor expression. To address this, we examined FeLV-T infection of cells expressing variable levels of FePit1 and other
gammaretroviral receptors in the presence of variable amounts of soluble cofactor, either RBD or the envelope surface subunit (SU). Cofactor–
receptor pairs fall into three groups with regard to mediating FeLV-T infection: those that are efficient at all concentrations tested, such as FePit1
and FeLIX; those requiring high expression of both cofactor and receptor; and those that are non-functional as receptors even at high expression.
This suggests that both expression levels and specific interactions with receptor and cofactor are critical for mediating entry of FeLV-T.
© 2006 Elsevier Inc. All rights reserved.Keywords: FeLV; Gammaretrovirus; Receptor; Viral entryIntroduction
Most simple retroviruses, including the major subgroups of
the gammaretrovirus feline leukemia virus (FeLV), appear to
require a single, cell-surface, small molecule transporter protein
for mediating the requisite receptor functions leading to entry
into host cells (Overbaugh et al., 2001; Tailor et al., 2003).
Receptor interaction is facilitated by the two subunits of the
viral envelope protein: the surface subunit (SU), which binds to
the receptor via the receptor binding domain (RBD); and the
transmembrane domain (TM), which tethers the envelope to the
plasma membrane and also contains the fusion machinery.
The four subgroups of FeLV use different receptors for entry
into cells. FeLV-A, which is highly conserved across different
decades and geographic locations (Donahue et al., 1988), is the
transmissible form of FeLV and uses the receptor FeTHTR1
(Mendoza et al., 2006). Chronic infection by FeLV-A in cats⁎ Corresponding author. Fax: +1 206 667 1535.
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development of new viral subgroups that recognize new cellular
receptors (Overbaugh et al., 2001; Rohn and Overbaugh,
1999a). For example, FeLV-C arises from FeLV-A by
characteristic point mutations leading to usage of FLVCR, a
heme transporter protein, for receptor function (Quigley et al.,
2000, 2004; Tailor et al., 1999). FeLV-A can also recombine
with related endogenous sequences to form FeLV-B, which uses
for a receptor either of two phosphate transporter proteins,
FePit1 or FePit2 (Anderson et al., 2001; Takeuchi et al., 1992).
The fourth subgroup, FeLV-T, is described below.
A combination of an insertion and single amino acid
changes, including changes at a conserved PHQ motif at the
N-terminus of SU (Overbaugh et al., 1988), are required to
convert FeLV-A into FeLV-T (Cheng et al., 2006; Gwynn et al.,
2000; Rohn et al., 1994, 1998). FeLV-T was the first identified
example of a naturally occurring simple retrovirus requiring two
host proteins to enter and infect, thereby representing a non-
classical entry pathway for gammaretroviruses (Anderson et al.,
2000; Cheng et al., 2006). In addition to requiring the phosphate
transporter FePit1, FeLV-T also requires the soluble cofactor
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resembling the RBD of envelope SU (Anderson et al., 2000).
Other soluble SUs from a diverse subset of gammaretro-
viruses paired with their cognate receptors [FeLV-A, gibbon ape
leukemia virus (GALV), amphotropic murine leukemia virus
(MLV)] have been tested as cofactor/receptor combinations
permissive for FeLV-T entry; among those, only cofactors
derived from endogenous FeLV, such as FeLIX or FeLV-B SU,
could function as efficient cofactors for FeLV-T infection
(Lauring et al., 2001). Moreover, these endogenous FeLV-
derived cofactors could only mediate efficient FeLV-T infection
in combination with the receptor FePit1 and not with the other
FeLV-B receptor, FePit2 (Lauring et al., 2001). This implied
that FeLV-T has specific requirements for the cofactor/receptor
combinations that will function to permit entry. However, a
more recent report suggests that at least one other murine
cofactor/receptor pair may function for entry of FeLV-T,
suggesting some promiscuity in FeLV-T receptor requirements,
at least in cells of other species (Barnett et al., 2003).
Other groups have shown that engineering a disruption or
deletion of the histidine of the N-terminal PHQ motif
conserved among gammaretroviruses resulted in murine
leukemia viruses (MLVs) that were not infectious using only
the cognate receptor (Bae et al., 1997). However, these
engineered MLVs could be rescued for infection by the
addition of soluble RBDs containing a wildtype histidine, in
the presence of the cognate cell-surface receptor (Barnett and
Cunningham, 2001; Barnett et al., 2001; Lavillette et al.,
2000). Thus, the entry requirements appeared similar to those
of naturally occurring FeLV-T. Interestingly, the engineered
MLVs could be rescued by a variety of heterologous soluble
RBD cofactors paired with cognate receptors, so long as the
receptors for both the virus envelope disrupted in PHQ and the
wildtype soluble RBD were present on the cell surface
(Lavillette et al., 2000). This broader specificity for heterol-
ogous receptor/cofactor pairs was subsequently reported for
other retroviruses, including two naturally occurring retro-
viruses: Mink cell focus-forming virus (MCF) and Porcine
endogenous retroviruses (PERVs). MCF can utilize the RBD
of its precursor virus form, Fr-MLV, bound to the Fr-MLV
receptor MCAT in the absence of its own receptor, Syg1, for
viral entry (Wensel et al., 2003). PERVs have also been shown
to gain entry by this non-classical pathway using a
combination of GALV sRBD and Pit1 (Lavillette and Kabat,
2004). These examples reflect less stringent cofactor/receptor
requirements than we had observed for FeLV-T.
One possible explanation for the differences in specificity
observed between our initial study and subsequent studies is the
differences in length of the soluble envelope constructs used to
generate soluble cofactors. We had previously used a soluble
form of the envelope SU, as we were interested in what is
occurring during natural infections in cats where this form of
envelope could be present on the surface of infected cells. In
contrast, MLV studies focused on an engineered form of the SU
that was truncated to remove the C-terminus, thus included
primarily the RBD. Additionally, differences in cell-surface
expression levels of the receptors between cell lines may becritical for determining entry, and this has not been carefully
addressed for FeLV-T.
To address these questions, we compared the effects of using
soluble RBD as compared to soluble SU cofactors on FeLV-T
infection. We constructed a number of different cell lines that
express varying amounts of cell surface receptor and found that
there are distinct thresholds for both cell-surface receptor
expression and cofactor levels that depend on the receptor
examined. These studies suggest that cells in the cat that are
infected by the other FeLV subgroups may all be targets of
infection by FeLV-T.
Results
Other cofactors besides those derived from endogenous FeLV
sequences can mediate FeLV-T infection
In order to determine whether the presence of the proline-rich
region and C-terminal domain of SU could account for
differences in the ability to serve as a cofactor for FeLV-T, we
constructed full-length SU and RBD-length versions of various
viral envelope proteins (Fig. 1A). All of the cofactors were
expressed as judged by Western blot, although there was a
substantial increase in the expression of FeLV-C-FSC sRBD and
GALV sRBD compared to the other proteins (data not shown).
Because we used a quantitative method of Western blotting, the
results of the initial Western blot could be used to adjust the
volume of each preparation so that roughly comparable amounts
of cofactor protein could be used for further studies (Fig. 1B).
As seen previously, cofactors derived from endogenous
FeLV sequences, FeLIX, FeLV-B-90Z SU and FeLV-B-90Z
sRBD, were able to mediate FeLV-T infection, in the presence
of FePit1 yielding titers on the order of ∼5×105 IU/ml (Fig. 2).
We also found that FeLV-T-infected cells expressing FLVCR
with FeLV-C-FSC SU or FeLV-C-FSC sRBD with titers nearing
to FePit1/FeLIX (1–5×105 IU/ml; Fig. 2). However, we did not
observe FeLV-T infection on MDTF-FeTHTR1 cells with
FeLV-A-61E SU or FeLV-A-61E sRBD cofactors (Fig. 2).
Furthermore, in keeping with results from our previous study,
there was no detectable infection with FePit1 using GALV
sRBD as a cofactor or FePit2 in combination with FeLV-B
cofactors (Fig. 2) (Lauring et al., 2001).
Increasing cofactor concentration can allow FeLV-A sRBD and
FeTHTR1 to act as FeLV-T receptors
To determine if increasing amounts of cofactor would impact
receptor specificity or efficiency, we tested a range of concentra-
tions of cofactors with their cognate receptors. For each cofactor,
we considered the volume per sample used on the normalized
Western blot in Fig. 1B, and for studies in Fig. 2, to be equal to one
equivalent. We tested two, four and eight times that equivalent.
Increasing the amount of cofactor in this way typically increased
the level of infection, although generally in increments of 2- to, at
most, 10-fold (Fig. 3). For example, titers of FeLV-T on MDTF-
FePit1 with one to eight equivalents of FeLIX ranged from 6×105
to 2×106 IU/ml. Titers of FeLV-T on MDTF-FLVCR with one to
Fig. 2. FeLV-T infection of MDTF cells in the presence of different receptor/
cofactor combinations. Results are shown as log10 titers of β-galactosidase-
positive foci per milliliter in a single cycle infection assay. The receptor
expressed in the cell line tested is shown above the graph, and the cofactor used
with it is shown at the bottom. The amount of cofactor used was one equivalent,
as shown in Fig. 1B. Arrows denote combinations where less than 10 β-
galactosidase-positive foci/ml were observed. The data shown are the results of
triplicate experiments and are typical of experiments performed on at least three
occasions.
Fig. 3. FeLV-T infection of MDTF cells expressing receptor and incubated with
increasing amounts of envelope-derived cofactor. Figure is the same as
described in the legend to Fig. 2, except that results using variable amounts of
cofactor (1, 2, 4 and 8 equivalents) are shown. The amount of cofactor added is
shown in a particular grayscale, as shown to the right. Results are representative
of triplicate experiments and are typical of experiments performed on at least
three occasions.
Fig. 1. Panel of soluble gammaretroviral envelope RBDs and SUs tested as entry
cofactors. (A) Schematic representation of the structure of each envelope-
derived cofactor. The name of each cofactor is indicated to the left of the boxes
representing the linear DNA sequence. The approximate location of the receptor
binding domain (RBD) within the SU is indicated at the top. (B) Western blot
analysis of a volume of conditioned supernatant that corresponds to one
equivalent unit of each envelope-derived cofactor. The amount loaded in each
lane was determined from the results of quantitative Western blot analysis of
equal amounts of each supernatant (not shown). Envelope-derived cofactors
were detected with the monoclonal antibody HA.11 to the C-terminal HA
epitope tags as described in Materials and methods. To the left of the blot are
approximate kilodaltons; to the right are the expected sizes of the SU and sRBD
constructs.
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ml and FeLV-C-SU increased from 1 to 5×105 IU/ml. The
exception was FeLV-A-61E sRBD, which increased from no
detectable infection with one equivalent of cofactor to∼103 IU/ml
with two equivalents,∼104 IU/mlwith four equivalents and almost
105 IU/ml with eight equivalents. Thus, the amount of cofactor had
varying impacts on infectivity, depending on the receptor/cofactor
combination.
Soluble envelope RBD facilitates FeLV-T infection more
efficiently than soluble SU
We found that, in most cases, the full-length soluble SU
cofactor and the corresponding soluble sRBD cofactor were
comparable in their ability to mediate FeLV-T infection. For
example, FeLV-T infection was similar with one equivalent of
either the SU or sRBD form of FeLV-B-90Z in the presence of
FePit1 (∼5×105 IU/ml; Fig. 3). However, there were subtle
differences (∼5-fold) in the infectivity of the SU as compared to
the sRBD form of FeLV-C-FSC in the presence of FLVCR. One
equivalent of FeLV-C-FSC sRBD facilitated titers of 1×105 IU/
ml whereas the same amount of FeLV-C-FSC SU facilitated
FeLV-T titers of 5×105 IU/ml (Fig. 3). Most notably, the sRBD
form of FeLV-A-61E facilitated a 1000-fold increase over theSU form in FeLV-T infectious titer on MDTF-FeTHTR1 cells,
5×104 IU/ml as compared to less than 10 IU/ml at eight
equivalents of cofactor.
A threshold amount of FeTHTR1 receptor and FeLV-A cofactor
is required for FeLV-T infection
Given that cofactor concentration impacted FeLV-T receptor
use for FeTHTR1/FeLV-A-61E sRBD, we wanted to test
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impact. For this purpose, we sorted for individual cells
expressing high, medium and low amounts of FeTHTR1. To
confirm the differences in receptor expression, we bound
saturating amounts of cofactor to cells, detected bound cofactor
with an antibody to an HA tag incorporated into each cofactor
and compared the amount of mean fluorescence (Fig. 4). The
results of this analysis show differing amounts of mean
fluorescence, indicative of variable amounts of receptor
expression (Fig. 4A).
We then tested these cell lines for the ability to mediate
FeLV-T infection with variable amounts of FeLV-A-61E SU and
FeLV-A-61E sRBD. Infection of cells was observable with
FeLV-A-61E SU only when the cells expressed the highest
levels of FeTHTR1 or when at least two equivalents of FeLV-A-
61E SU were introduced (Fig. 4B). Hence, the longer SU forms
of envelope can function in FeLV-T infection, but either the
receptor or the cofactor must be at a medium level, and it is most
efficient if they are both present at high levels. As noted above,
FeLV-T infection is higher in the presence of the FeLV-A sRBD
versus the SU, and this was particularly true at lower levels of
receptor or cofactor (Fig. 4C).
High expression of FePit1/GALV sRBD cannot rescue FeLV-T
infection
We constructed cell lines with variable expression of
FePit1 in order to test whether increased expression might
rescue infection with GALV sRBD, as they had for the high-
expressing FeTHTR1-H cells with FeLV-A SU and sRBD.
The expression levels of FePit1 on the selected cell clones
were verified by FACS analysis using saturating levels of the
FeLV-B SU (Fig. 5A).
There was some impact of FePit1 expression level on
FeLV-T infection in the presence of the FeLV-B cofactors, either
FeLV-B SU (Fig. 5B) or FeLV-B sRBD (Fig. 5C): FeLV-T
infection was ∼5-fold higher in the presence of these cofactors
with cells expressing medium levels of FePit1 versus low levels.
There was no difference between the medium- and high-
receptor-expressing cells (data not shown). We found that, even
with high levels of FePit1 expression, GALV sRBD was notFig. 4. Analysis of FeLV-T infection of MDTF cells expressing increasing
FeTHTR1 in the presence of variable amounts of FeLV-A envelope-derived
cofactors. (A) Fluorescence histograms representing saturation binding of the
FeLV-A SU HA to single clone populations of MDTF cells; cell lines were
derived from single clones isolated by flow cytometry, as described in Materials
and methods. The black histogram represents high expressing cells, dark gray
histogram represents medium expressing cells, light gray histograms represent
low expressing cells, and open histograms represent the high expressing cells
with no cofactor added. (B) Infection of MDTF-FeTHTR1 cells using cells from
panel A and different equivalent amounts of the FeLV-A SU HA cofactor. (C)
Infection of MDTF-FeTHTR1 cells using cells from panel A and different
equivalent amounts of the FeLV-A sRBD HA cofactor. For panels B and C, the
results for each amount of cofactor added are shown in the grayscale indicated to
the right of the figure. Results are shown as log10 β-galactosidase-positive foci
per ml (IU/ml). Results are representative of triplicate experiments and are
typical of experiments performed on at least three occasions. An arrow indicates
that infection was less than 10 IU/ml. n.d. indicates experiment not done.able to mediate FeLV-T infection, even at greater than eight
equivalents (Fig. 5D). This suggests that there is an absolute
block to infection that cannot be overcome by increasing the
receptor or cofactor.
Feline fibroblast cells express an intermediate level of
FeTHTR1 and FePit1 relative to engineered cell lines
We have shown that receptor and cofactor expression are
critical to the efficiency of FeLV-T infection. In order to
determine how these receptor levels compare to the endogenous
Fig. 5. FeLV-T infection of cells expressing variable levels of FePit1 and with variable levels of cofactors. (A) Fluorescence histograms collected through flow
cytometry representing saturation binding of the FeLV-B SU HA to single clone populations of MDTF cells expressing different amounts of the FePit1 receptor, as
described in Materials and methods. The black histogram represents high expressing cells, dark gray histogram represents medium expressing cells, light gray
histograms represent low and lowest expressing cells. (B) Infection of MDTF-FePit1 cells using cells from panel A and different equivalent amounts of the FeLV-B SU
HA cofactor. (C) Infection of MDTF-FePit1 cells using cells from panel A and different equivalent amounts of the FeLV-B sRBDHA cofactor. (D) Infection of MDTF-
FePit1 cells using cells from panel A and different equivalent amounts of the GALV sRBDHA cofactor. For panels B–D, the results for each amount of cofactor added
are shown in the grayscale indicated to the right of the figure. Results are shown as log10 β-galactosidase-positive foci per ml (IU/ml). Results are also representative of
triplicate experiments and are typical of experiments performed on at least three occasions. An arrow indicates infection was less than 10 IU/ml.
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line to the cell lines expressing variable amounts of receptor
(low, medium and high levels of FeTHTR1 or FePit1) in a
single FACS experiment using the same amounts of cofactor
(Fig. 6). The expression of FeTHTR1 on AH927 is in the range
between the medium- and high-expressing MDTF-FeTHTR1
cells (Fig. 6). The expression of FePit1 on AH927 is in the range
between the low- and medium-expressing MDTF-FePit1 cells
(Fig. 6). Thus, the MDTF cells engineered to express the
various receptors did not express these receptors at levels that
were aberrantly high compared to those found in a susceptible
feline cell line.
Discussion
The naturally arising FeLV-T requires two host cell proteins
for entry, a multiple membrane-spanning transport protein and
a soluble cofactor. This is in contrast to its progenitor virus,FeLV-A, which only requires the membrane-spanning receptor.
To better understand the basis for FeLV-T entry and specificity,
we examine the specific cofactor/receptor requirements, as well
as how cofactor and receptor levels influence FeLV-T
specificity. We found that FeLV-T can utilize other combina-
tions of cofactor and cell-surface receptor that were previously
untested. For example, FeLV-T can enter cells using the FLVCR
and either FeLV-C-FSC SU or sRBD with comparable
efficiency to FePit1/FeLIX. We also found that increasing the
receptor expression and cofactor concentration can render some
previously inefficient receptor/cofactor pairs, such as FeTHTR1
with FeLV-A-61E SU or sRBD, more efficient for FeLV-Tentry.
Finally, we found that, even using very high amounts of
receptor and cofactor, some combinations of receptor/cofactor
pairs remain unable to mediate FeLV-T infection. A caveat to
interpreting our study is that, even though the FeLV-T particles
and the cofactor were both generated by similar transfection
methods, we did not define precise ratios of the FeLV-T
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type would allow a more direct comparison of the stoichiometry
of the critical proteins.
We noted, in some cases, that FeLV-T infection was higher in
the presence of equivalent levels of sRBD compared to SU. This
was most pronounced for FeTHTR1/FeLV-A sRBD. This
suggests that there is some reduction in efficiency to cofactor
rescue in the presence of the C-terminus that is not simply due to
differences in sRBD versus the full-length SU. Rather, this
difference may be a reflection of the regulatory interactions
between N- and C-termini in the gammaretroviral entry, as has
been proposed previously for variants of MLV that require a
soluble cofactor (Barnett and Cunningham, 2001; Lu and Roth,
2003).
The levels of receptor expression in the cell lines engineered
to express the receptors examined here were similar to the
endogenous levels found in a feline cell line, AH927. AH927
cells expressed levels of FePit1 that would be predicted to
permit efficient entry of FeLV-T, even in the presence of lower
levels of soluble cofactor. FeTHTR1 levels were also moderate
to high in feline cells, but they could still be inadequate to
permit a high level of FeLV-T infection, particularly when the
full-length FeLV-A SU is the entry cofactor. Indeed, this may
explain why in previous studies using AH927 cells to test theFig. 6. Relative expression of FeTHTR1 and FePit1 on feline fibroblasts, AH927, c
saturation binding of 61E sRBD HA on AH927 and MDTF alone (gray filled profile
outline) and MDTF-FeTHTR1-high (black solid outline). Bottom left: fluorescenc
saturation binding of FeLV-A-61E sRBD HA (black solid profile). Top right: fluores
MDTF alone (gray filled profile), MDTF-FePit1-lowest (dotted outline), MDTF-Fe
Bottom right: fluorescence histograms representing AH927 alone (gray filled profile) apotential of FeLV-A to function as a cofactor, which were done
prior to the identification of the FeLV-A receptor (Mendoza et
al., 2006), infection with FeLV-Twas negligible (Lauring et al.,
2001). These studies underscore the importance of both receptor
expression and cofactor concentration in defining which cells
are infectable by FeLV-T in vivo. The importance of cell-surface
receptor concentrations to the efficiency of infection has been
previously shown for a number of other retroviruses (Chung et
al., 1999; Kuhmann et al., 2000; Kurre et al., 1999; Platt et al.,
1998; Tailor et al., 2000). With the additional requirement of a
soluble cofactor, it seems reasonable to suppose that the overall
efficiency of entry should depend on the concentrations of both
cell-surface receptor and soluble cofactor, as we have shown
here.
These findings have implications for the tropism of FeLV-T
in the infected cat. FeLV-T was originally identified as a T-cell
tropic variant (Donahue et al., 1991; Overbaugh et al., 1988),
which was subsequently explained by the fact that the
endogenous cofactor FeLIX is expressed at the highest levels
in T cells (Anderson et al., 2000; Lauring et al., 2001). The
studies described here suggest that other cells may be targets of
infection in FeLV-T infected cats that are co-infected with
FeLV-A and FeLV-C. FeLV-C is relatively uncommon, but,
when present, largely targets hematopoietic cells; thus in catsompared to the MDTF cell lines. Top left: fluorescence histograms representing
), MDTF-FeTHTR1-low (dotted outline), MDTF-FeTHTR1-medium (gray solid
e histograms representing AH927 alone (gray filled profile) and AH927 with
cence histograms representing saturation binding of FeLV-B-90Z sRBD HA on
Pit1-medium (gray solid outline) and MDTF-FePit1-high (black solid outline).
nd AH927 with saturation binding of FeLV-B-90Z sRBDHA (black solid profile).
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targets of co-infection. In fact, because FeLV-T does not cause
superinfection interference, presumably due to the unique
nature of its unusual receptor requirements, it is possible that
these co-infected cells would then accumulate a high copy
number of FeLV-T, leading to greater cytopathic effect. A recent
study provides biochemical evidence that reduced binding
affinity of the TR1.3 MLV leads to decreased superinfection
interference and greater cytopathicity (Murphy et al., 2006). To
date, we have not been able to reliably show binding of FeLV-T
to the FePit1/FeLIX complex by flow cytometry (Cheng, H.H.
and Overbaugh J., unpublished data), suggesting that affinity of
the virus for the cofactor/receptor complex is likely to be low.
By analogy to the TR1.3 MLV, reduced binding affinity may
also contribute to the cytopathic properties of FeLV-T.
While cases of FeLV-C infection in cats are rare, all FeLV-
infected cats harbor FeLV-A (Rohn and Overbaugh, 1999b).
Because FeLV-A has a broad cell tropism for feline cells, a
range of cells expressing FeTHTR1 and infected with FeLV-A
are potential targets of FeLV-T. However, infection in the
presence of the full-length FeLV-A SU cofactor is inefficient,
and it is the truncated version of FeLV-A envelope that is most
effective as an entry cofactor. Such truncated versions of the
FeLV-A envelope have been detected in tumors (Rohn et al.,
1994), but their potential impact on FeLV-T infection in the
infected cat is unknown.
Here we show that specificity of FeLV-T for its receptor is of
three varieties: the first are receptor/cofactor pairs where
infection is less sensitive to expression levels, suggesting
high-affinity, optimal interactions between the virus and the
receptor/cofactor. A second variety includes receptor/cofactor
combinations where FeLV-T infection is more dependent on
expression levels to meet the threshold for infection, suggesting
that viral envelope may have lower affinity for these receptor
complexes. A third variety are receptor/cofactor pairs that are
not functional at any concentration, suggesting that FeLV-T
cannot productively interact with these proteins to gain entry
into the cell. The presumed endogenous receptor complex,
FePit1/FeLIX, is likely to play a critical role in FeLV-T infection
in the cat, but other receptor/cofactor combinations may also
contribute to replication of FeLV-T in cats that are co-infected
with multiple FeLV variants. Thus, the targets for FeLV-T
infection in the host may be defined in part by how the infecting
FeLV-A virus itself has diversified.
Materials and methods
Cell culture
The MDTF murine fibroblast cell line has been described
previously (Lander and Chattopadhyay, 1984), as has the
MDTF-FePit1 line (Anderson et al., 2001), MDTF-FePit2
(Anderson et al., 2001), MDTF-FLVCR (Cheng et al., 2006)
and MDTF-FeTHTR1 (Mendoza et al., 2006). All receptor-
expressing MDTF cell lines, including those described below,
were maintained in complete DMEM (Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum,100 U penicillin/ml, 100 μg streptomycin/ml, 0.25 mg
amphotericin fungicide/ml, and 2 mM L-glutamine), containing
1.0 mg G418/ml (Geneticin, Gibco).
Construction of cell lines with variable amounts of receptor
expression
Cells expressing variable receptor levels, either FePit1 or
FeTHTR1, were made by introducing retroviral vectors L
(FePit1)SN (Anderson et al., 2001) or L(FeTHTR1)SN
(Mendoza et al., 2006) into MDTF cells. Particles containing
the relevant vector genome were generated in 293T cells using
transient transfection with the following plasmids: amphotropic
MuLV envelope (SV-A-MLV-env (Landau et al., 1991)), a
construct encoding FeLV gag and pol (61E-LTR-Δψ gag-pol
(Sugai et al., 2001)), and either L(FeTHTR1)SN or L(FePit1)
SN as appropriate. 2×105 MDTF cells were transduced with
these particles in a 4 cm tissue culture dish and grown in
selection media until approximately 75–80% confluence—
about 4–6 days (Anderson et al., 2001), at which time they were
sorted by flow cytometry. For that purpose, 2 ml of conditioned
media containing FeLV-A-61E SU HA or FeLV-B-90Z SU HA
were incubated with a pool of 2×105 cells transduced with L
(FeTHTR1)SN or L(FePit1)SN respectively, in a 5 ml Falcon
2054 tube for 1 h on a rotator at 4 °C. Cells were pelleted in a
swing-bucket tabletop centrifuge at 1200 RPM for 5 min at
4 °C, and media was aspirated. Washes were done by gently
adding 1 ml of cold Hanks buffered saline solution with
magnesium and calcium and 2% fetal bovine serum (WB) to
resuspend the cells. Cells were pellet again at 1200 RPM for
5 min at 4 °C and WB was aspirated. Cells were then resus-
pended in 200 μl of a 1:1000 dilution of an ascites concentrate
of monoclonal antibody HA.11 (Covance, Berkeley, CA) in WB
and incubated on ice for a minimum of 90 min. Primary
antibody incubation was followed by two washes with 1 ml cold
WB. Cells were resuspended in 150 μl of a 1:100 dilution of
R-phycoerythrin-conjugated goat anti-mouse antibody (DAKO,
Carpinteria, CA) in WB and incubated on ice and protected
from light for a minimum of 30 min. Secondary antibody
incubation was followed by a final wash in cold WB and then
resuspended in 300 μl WB and stored on ice and protected from
light until flow cytometric analysis. Cells were analyzed on a
Vantage Flow Cytometer, and individually sorted based on
high, medium and low fluorescence into wells of a 96-well
tissue culture dish with each well containing 200 μl of
conditioned selection media that was filtered through a
0.22 μM filter. After 5 days, surviving clonal populations
were expanded in selection media to a 12-well dish.
Clonal populations underwent a second round of screening
for receptor expression by repeating the binding assay from
above, except that 1×105 cells derived from each single clone
were used. A subset of cells were frozen for storage at the time
of the second screening. After the second screen, three or four
representative clonal populations were selected, expanded and
frozen back. A third binding assay was performed using 1 ml of
cofactor (at least 100× the minimal volume to detect maximal
binding in previous experiments using polyclonal cells) on each
177H.H. Cheng et al. / Virology 359 (2007) 170–178of these final cell lines as confirmation of their receptor
expression.
The binding assay used for confirmation of the newly
constructed cell lines is the same assay used to analyze receptor
expression of other cell lines and has been previously described
(Lauring et al., 2001).
Expression of HA-tagged FeLIX and viral RBDs and SUs
The expression constructs CS2-FeLV-B-90Z-SU-HA, CS2-
FeLV-B-90Z-RBD-HA, CS2-FeLV-A-61E-SU-HA, CS2-
FeLIX-HA and CS2-GALV-SU1–262-HA have been previously
described (Lauring et al., 2001). CS2-FeLV-A-61E-sRBD-HA,
CS2-FeLV-C-FSC-SU HA and CS2-FeLV-C-FSC-sRBD HA
were made using the same method (primers available on
request). All constructs were verified by nucleotide sequence
analyses. Conditioned media containing soluble retrovirus
sRBDs, SUs, and FeLIX were generated with the plasmids
mentioned above by transient transfection of 293T cells using a
calcium phosphate protocol as described previously (Lauring et
al., 2001).
Virus production and infection assays
Pseudotyped virus was made by calcium phosphate
transfection of 293T cells (Mammalian Transfection Kit,
Stratagene) with FeLV-61E-gag-pol (61E-LTR-ΔΨ-gal-pol),
an MLV-derived reporter gene that expresses β-galactosidase
(pRT43.2Tnlsβgal-1) and the desired FeLV-T envelope con-
struct, as described previously (Sugai et al., 2001). Viral
infectivity was assayed using a single-cycle infection assay
described previously (Anderson et al., 2001).
Immunoprecipitation and Western blot analysis
Initial steps of immunoprecipitation and Western blot
analysis were performed as described previously (Lauring et
al., 2001). The blot membrane was probed with 10 μl rabbit
polyclonal HA.11 antibody (Covance, Berkeley, CA), followed
by thorough washing and probing with 1.8 μl of Alexa Fluor
680 goat anti-rabbit secondary antibody (Molecular Probes,
Eugene, OR) in 10 ml of antibody dilution buffer for 1 h at room
temperature, protected from light. The blot was washed again
with phosphate buffered saline (PBS) containing 0.1% Tween
20 and rinsed in PBS. Proteins bound with antibodies were
detected and quantified using the Odyssey Infrared Imaging
System according to manufacturer's protocol (LI-COR Bios-
ciences, Lincoln, NB).
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